Online citations, reference lists, and bibliographies.
← Back to Search

Claudin-4 Expression Predicts Survival In Pancreatic Ductal Adenocarcinoma

K. Tsutsumi, N. Sato, R. Tanabe, K. Mizumoto, Katsuya Morimatsu, Tadashi Kayashima, H. Fujita, K. Ohuchida, T. Ohtsuka, S. Takahata, M. Nakamura, M. Tanaka
Published 2011 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BackgroundIdentification of prognostic markers would be useful in the clinical management of patients with pancreatic ductal adenocarcinoma (PDAC). The clinical relevance of claudin-4 (CLDN4), recently identified as overexpressed in PDAC, is unknown.MethodsUsing quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR), we analyzed CLDN4 mRNA expression in a panel of 9 pancreatic cancer cell lines and formalin-fixed paraffin-embedded (FFPE) tissues from 100 patients with PDAC. The CLDN4 expression levels were then correlated with clinicopathological variables and patient outcome. We also performed immunohistochemical analysis in 20 FFPE samples of PDAC to investigate the expression of CLDN4 protein.ResultsIncreased expression of CLDN4 was confirmed in all the pancreatic cancer cell lines tested compared with normal ductal epithelial cells and fibroblasts. We found that low expression of CLDN4 was significantly associated with shorter survival in patients with PDAC (hazard ratio; 1.362, 95% confidence interval; 1.011–1.873, P = 0.0419). Patients with high CLDN4 expression survived longer for a median of 63.0 months, compared with 14.7 months in patients with low CLDN4 expression (P = 0.0067). In immunohistochemical analysis, the level of CLDN4 mRNA expression was significantly correlated with the expression of CLDN4 protein (P = 0.0168).ConclusionIncreased expression of CLDN4 mRNA predicts better prognosis in PDAC.
This paper references
10.1002/jcp.10133
Antagonistic effect of NK4 on HGF/SF induced changes in the transendothelial resistance (TER) and paracellular permeability of human vascular endothelial cells
T. Martin (2002)
10.1016/S0016-5085(08)64009-3
951 High Expression of Heparanase Is Significantly Associated with Dedifferentiation and Lymph Node Metastasis in Patients with Pancreatic Ductal Adenocarcinomas and Correlated to PDGFA and Via HIF1a to HB-EGF and bFGF
A. Hoffmann (2008)
10.1158/1078-0432.CCR-09-0227
SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer
A. Blackford (2009)
10.1158/1078-0432.CCR-04-1581
Quantitative Assessment of Telomerase Activity and Human Telomerase Reverse Transcriptase Messenger RNA Levels in Pancreatic Juice Samples for the Diagnosis of Pancreatic Cancer
K. Ohuchida (2005)
10.1159/000055903
Expression of E-Cadherin, Alpha- and Beta-Catenins in Patients with Pancreatic Adenocarcinoma
Y. Joo (2002)
10.1097/00000658-200201000-00007
p16INK4a is a Prognostic Marker in Resected Ductal Pancreatic Cancer: An Analysis of p16INK4a, p53, MDM2, an Rb
B. Gerdes (2002)
Ductal adenocarcinoma of the pancreas. Histopathological features and prognosis.
A. Tannapfel (1992)
10.1245/s10434-010-1033-0
Prognostic Impact of Perioperative Serum CA 19-9 Levels in Patients with Resectable Pancreatic Cancer
N. Kondo (2010)
10.1016/S1072-7515(01)00925-5
Ductal adenocarcinoma of the body and tail of the pancreas.
C. Sperti (1997)
10.1016/J.EJCA.2005.04.044
Molecular prognostic markers in pancreatic cancer: a systematic review.
G. Garcea (2005)
10.1016/j.jss.2010.02.010
The expression of claudin-1, claudin-2, claudin-3, and claudin-4 in gastric cancer tissue.
H. Jung (2011)
Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer.
P. Michl (2003)
10.1097/00006676-200208000-00002
High Expression of Vascular Endothelial Growth Factor Predicts Early Recurrence and Poor Prognosis after Curative Resection for Ductal Adenocarcinoma of the Pancreas
M. Niedergethmann (2002)
10.1097/00006676-200305000-00006
Expressions of Angiogenic Factors in Pancreatic Ductal Carcinoma: A Correlative Study with Clinicopathologic Parameters and Patient Survival
Kenichi Kuwahara (2003)
10.1067/MCN.2002.129579
Epidemiology and risk factors
T. Yeo (2002)
Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions
研宙 大内田 (2005)
Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium.
H. Long (2001)
10.1158/0008-5472.CAN-05-4203
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.
E. Giovannetti (2006)
10.1097/01.sla.0000217673.04165.ea
One Thousand Consecutive Pancreaticoduodenectomies
J. Cameron (2006)
10.1016/j.ejpb.2010.03.003
Claudin-4-targeting of diphtheria toxin fragment A using a C-terminal fragment of Clostridium perfringens enterotoxin.
H. Kakutani (2010)
10.1007/s10120-008-0497-0
Expression of tight-junction-associated proteins in human gastric cancer: downregulation of claudin-4 correlates with tumor aggressiveness and survival
S. Ohtani (2008)
10.2310/7290.2007.00010
Radiolabeled Anti-Claudin 4 and Anti-Prostate Stem Cell Antigen: Initial Imaging in Experimental Models of Pancreatic Cancer
C. Foss (2007)
10.1158/1078-0432.CCR-1157-03
Comprehensive Analysis of Matrix Metalloproteinase and Tissue Inhibitor Expression in Pancreatic Cancer
L. Jones (2004)
WHO Classification of Tumours of the Digestive System
F. Bosman (2010)
10.1007/978-3-642-82982-6
TNM Classification of Malignant Tumours
L. Sobin (1987)
10.1016/S0002-9440(10)63911-9
Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays.
C. Iacobuzio-Donahue (2003)
10.1016/S1525-1578(10)60449-7
Towards quantitative mRNA analysis in paraffin-embedded tissues using real-time reverse transcriptase-polymerase chain reaction: a methodological study on lymph nodes from melanoma patients.
H. Abrahamsen (2003)
10.1200/JCO.2006.08.4798
Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma.
U. Halm (2006)
10.1186/1471-2407-6-186
The claudin gene family: expression in normal and neoplastic tissues
K. J. Hewitt (2006)
10.3322/caac.20006
Cancer Statistics, 2009
A. Jemal (2009)
Invasion-specific genes in malignancy: serial analysis of gene expression comparisons of primary and passaged cancers.
B. Ryu (2001)
10.1016/S0002-9440(10)63721-2
Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4.
S. Kominsky (2004)
10.1038/labinvest.3700303
Reliable gene expression measurements from degraded RNA by quantitative real-time PCR depend on short amplicons and a proper normalization
J. Antonov (2005)
Ultrastructural differences in junctional intercellular communication between highly and weakly metastatic clones derived from rat mammary carcinoma.
J. Ren (1990)
bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome.
F. Sinicrope (1996)
10.1593/NEO.08292
High expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF.
A. Hoffmann (2008)
10.1007/s11605-009-0978-4
S100A4 mRNA is a Diagnostic and Prognostic Marker in Pancreatic Carcinoma
N. Ikenaga (2009)
10.1016/S0016-5085(98)70209-4
Identification, culture, and characterization of pancreatic stellate cells in rats and humans.
M. Bachem (1998)
10.1200/JCO.2001.19.4.1118
Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression.
H. Yamamoto (2001)
10.1016/J.AMJSURG.2007.02.026
Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas.
M. Müller (2008)
10.1002/JSO.1033
Expression of Bcl‐2 and p53 protein in resectable invasive ductal carcinoma of the pancreas: Effects on clinical outcome and efficacy of adjuvant chemotherapy
Y. Nio (2001)
10.1016/j.humpath.2010.01.005
Expression pattern and prognostic significance of claudins 1, 4, and 7 in nasopharyngeal carcinoma.
C. Hsueh (2010)
10.1891/9781617052828.0021
Pancreatic cancer.
T. Yeo (2002)
Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer.
C. D. Hough (2000)
10.1111/j.1349-7006.2009.01239.x
Therapeutic antitumor efficacy of monoclonal antibody against Claudin‐4 for pancreatic and ovarian cancers
M. Suzuki (2009)
10.1080/110241599750006811
Prognosis of human pancreatic adenocarcinoma: review of clinical and histopathological variables and possible uses of new molecular methods.
M. Eskelinen (1999)
10.1091/MBC.12.2.279
Na,K-ATPase β-Subunit Is Required for Epithelial Polarization, Suppression of Invasion, and Cell Motility
S. A. Rajasekaran (2001)
10.1002/bjs.4484
Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma
M. Wagner (2004)
10.1016/S0016-5085(00)70351-9
Claudins regulate the intestinal barrier in response to immune mediators.
T. Kinugasa (2000)
Na,K-ATPase beta-subunit is required for epithelial polarization, suppression of invasion, and cell motility.
S. A. Rajasekaran (2001)
10.1136/gut.2004.047191
Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry
M. Carpelan-Holmström (2005)
10.1053/GAST.2001.27124
Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin.
P. Michl (2001)



This paper is referenced by
10.1016/j.lfs.2020.117754
Bacteriotherapy in gastrointestinal cancer.
S. Soleimanpour (2020)
10.1002/cncy.21392
Claudin‐4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology
V. Jo (2014)
10.3390/ijms140918148
Emerging Roles of Claudins in Human Cancer
Mi jeong Kwon (2013)
CLAUDINA- 3 E CLAUDINA- 4, POTENCIAIS MARCADORES DE AGRESSIVIDADE NO CARCINOMA ENDOMETRIAL TIPO I
Ângela Favorito Santarém Tonon (2013)
Expression Pattern and Prognostic Significance of Claudin 1 , 4 and 7 in Pancreatic Cancer Arsenal
Sezgin Alikanoglu ()
10.1101/254375
Building a tumor atlas: integrating single-cell RNA-Seq data with spatial transcriptomics in pancreatic ductal adenocarcinoma
Reuben M Moncada (2018)
10.7314/APJCP.2015.16.10.4387
Expression pattern and prognostic significance of claudin 1, 4 and 7 in pancreatic cancer.
A. Alikanoǧlu (2015)
10.1007/s11626-019-00336-5
Pancreatic duct-like cell line derived from pig embryonic stem cells: expression of uroplakin genes in pig pancreatic tissue
N. Talbot (2019)
10.2147/OTT.S99461
Clinicopathological significance of claudin 4 expression in gastric carcinoma: a systematic review and meta-analysis
X. Chen (2016)
10.3748/wjg.v20.i31.10813
Targeting tight junctions during epithelial to mesenchymal transition in human pancreatic cancer.
D. Kyuno (2014)
10.1371/journal.pone.0067496
Regulation of the Epithelial-Mesenchymal Transition by Claudin-3 and Claudin-4
X. Lin (2013)
10.9734/JCTI/2015/19336
Differential Expression of Claudin-1, Claudin-3, and Claudin-4 in Bladder Lesions
T. D. Kokenek-Unal (2015)
10.1517/14728222.2012.708340
Targeting claudin-4 in human pancreatic cancer
T. Kojima (2012)
10.1007/978-1-4614-4884-6_3
Comparative Effects of the Preventive Effect of Pregnancy, Steroidal Hormones, and hCG in the Transcriptomic Profile of the Rat Mammary Gland
J. Russo (2013)
10.1007/978-1-4614-4884-6
Role of the Transcriptome in Breast Cancer Prevention
J. Russo (2012)
10.1593/NEO.12942
Tight junction proteins claudin-3 and claudin-4 control tumor growth and metastases.
Xiying Shang (2012)
10.1007/s00384-020-03535-9
The bacterial instrument as a promising therapy for colon cancer
Atieh Yaghoubi (2020)
10.1097/MPA.0000000000000774
Immunohistochemical Antibody Panel for the Differential Diagnosis of Pancreatic Ductal Carcinoma From Gastrointestinal Contamination and Benign Pancreatic Duct Epithelium in Endoscopic Ultrasound-Guided Fine-Needle Aspiration
A. Furuhata (2017)
10.1245/s10434-012-2381-8
Low Expression of Junctional Adhesion Molecule A Is Associated with Metastasis and Poor Survival in Pancreatic Cancer
D. Fong (2012)
10.1186/s12885-018-4141-z
High-level cytoplasmic claudin 3 expression is an independent predictor of poor survival in triple-negative breast cancer
A. Jääskeläinen (2018)
10.1007/s12253-015-9936-5
Expression of Tight Junction Components in Hepatocyte-Like Cells Differentiated from Human Embryonic Stem Cells
Boglárka Erdélyi-Belle (2015)
10.1016/j.anndiagpath.2015.10.005
Distinctive immunostaining of claudin-4 in spiradenomas.
N. Yigit (2016)
10.4251/wjgo.v9.i4.153
Effect of Clostridium perfringens enterotoxin on gastric cancer cells SGC7901 which highly expressed claudin-4 protein
Zheng-Yun Liang (2017)
10.1097/MPA.0000000000000233
Intraductal papillary mucinous neoplasms of the pancreas.
M. Tanaka (2014)
10.1124/mol.112.079798
Claudin-3 and Claudin-4 Regulate Sensitivity to Cisplatin by Controlling Expression of the Copper and Cisplatin Influx Transporter CTR1
Xiying Shang (2013)
10.1016/j.pan.2018.10.009
Claudin 7 as a possible novel molecular target for the treatment of pancreatic cancer.
Norimitsu Okui (2019)
10.1007/s12105-014-0559-z
Overexpression of Claudin-1 is Associated with Advanced Clinical Stage and Invasive Pathologic Characteristics of Oral Squamous Cell Carcinoma
Kraisorn Sappayatosok (2014)
10.3390/ijms140510412
Claudins Overexpression in Ovarian Cancer: Potential Targets for Clostridium Perfringens Enterotoxin (CPE) Based Diagnosis and Therapy
D. English (2013)
10.1016/j.hpb.2016.05.004
Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinoma.
W. Petrushnko (2016)
10.1007/s11307-017-1112-8
Imaging of Claudin-4 in Pancreatic Ductal Adenocarcinoma Using a Radiolabelled Anti-Claudin-4 Monoclonal Antibody
J. Torres (2017)
10.1007/s12032-014-0951-2
Low expression of claudin-4: an indicator of recurrence in esophageal squamous cell carcinoma after Ivor Lewis esophagectomy?
M. Shi (2014)
Semantic Scholar Logo Some data provided by SemanticScholar